Josh Jennings
Stock Analyst at Morgan Stanley
(2.55)
# 2,236
Out of 5,120 analysts
14
Total ratings
54.55%
Success rate
18.14%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Josh Jennings
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DCBO Docebo | Maintains: Overweight | $49 → $53 | $19.64 | +169.86% | 5 | Nov 10, 2023 | |
| PODD Insulet | Maintains: Outperform | $350 → $300 | $256.62 | +16.90% | 3 | Aug 9, 2023 | |
| BFLY Butterfly Network | Initiates: Outperform | $20 | $3.82 | +423.56% | 1 | Jun 21, 2021 | |
| MDWD MediWound | Initiates: Outperform | $63 | $18.12 | +247.68% | 1 | Sep 28, 2017 | |
| CTSO Cytosorbents | Initiates: Outperform | $7 | $0.68 | +934.43% | 1 | Jun 7, 2017 | |
| EW Edwards Lifesciences | Maintains: Outperform | $43 → $40 | $82.65 | -51.60% | 3 | Dec 7, 2016 |
Docebo
Nov 10, 2023
Maintains: Overweight
Price Target: $49 → $53
Current: $19.64
Upside: +169.86%
Insulet
Aug 9, 2023
Maintains: Outperform
Price Target: $350 → $300
Current: $256.62
Upside: +16.90%
Butterfly Network
Jun 21, 2021
Initiates: Outperform
Price Target: $20
Current: $3.82
Upside: +423.56%
MediWound
Sep 28, 2017
Initiates: Outperform
Price Target: $63
Current: $18.12
Upside: +247.68%
Cytosorbents
Jun 7, 2017
Initiates: Outperform
Price Target: $7
Current: $0.68
Upside: +934.43%
Edwards Lifesciences
Dec 7, 2016
Maintains: Outperform
Price Target: $43 → $40
Current: $82.65
Upside: -51.60%